香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致之任何損失承擔任何責任。 海外監管公告 國藥集團一致藥業股份有限公司 2025 年度業績快報 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 茲載列國藥控股股份有限公司旗下一間 A 股及 B 股於深圳證券交易所上市的附屬公司，國藥 集團一致藥業股份有限公司，在深圳證券交易所網站刊登的《國藥集團一致藥業股份有限公 司 2025 年度業績快報》，僅供參閱。 承董事會命 國藥控股股份有限公司 董事長 晉斌 中國，上海 2026 年 3 月 17 日 於本公告日期，執行董事為連萬勇先生及楊秉華先生；非執行董事為晉斌先生、陳啟宇先生、祖敬 先生、邢永剛先生、馬躍先生、陳玉卿先生、文德鏞先生及李瑩女士；獨立非執行董事為李培育先 生、吳德龍先生、俞衛鋒先生、石晟昊先生及陳威如先生。 证券代码：000028、200028 证券简称：国药一致、一致 B 公告编号：2026-04 国药集团一致药业股份有限公司 2025年度 ...

Group 1 - The board of directors of China National Pharmaceutical Group Corporation (referred to as "the company" or "China National Pharmaceutical") held its second temporary meeting of the tenth board on February 27, 2026, via electronic communication, with all 9 attending directors present [2] - The board approved the proposal regarding the organizational structure adjustment of the headquarters, with a unanimous vote of 9 in favor, 0 against, and 0 abstentions [2] - The board also approved the proposal for the liquidation and deregistration of Jilin Dinghe Pharmaceutical Technology Co., Ltd., with the same voting results, indicating a focus on improving management efficiency and quality [3]

2025年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要提示： ● 预计2025年度实现归属于上市公司股东的净利润105,500万元到121,500万元，同比增长64.20%到 89.11%。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000028、200028 证券简称：国药一致、一致B 公告编号：2026-01 国药集团一致药业股份有限公司 ● 预计2025年度实现归属于上市公司股东的扣除非经常性损益的净利润99,600万元到115,600万元，同比 增长71.38%到98.91%。 一、本期业绩预计情况 （一）业绩预告期间：2025年1月1日至2025年12月31日。 （二）业绩预告情况：预计净利润为正值且属于同向上升50%以上情形 ■ 二、与会计师事务所沟通情况 国药一致（简称"公司"）就业绩预告有关事项已与会计师事务所进行预沟通，公司与会计师事务所在业 绩预告方面不存在分歧。本次业绩预告相关的财务数据是公司财务部门初步估算得出，未经会计师事务 所审计。 三、业绩变动原因说明 2025年度，在行业政策复杂多变，市场竞 ...

Group 1 - The company held its seventh temporary board meeting on November 27, 2025, with all nine directors present, confirming compliance with legal and regulatory requirements [2] - The board approved the "Valuation Enhancement Plan" with a unanimous vote of 9 in favor [3] - The board also approved the revision of the "Strategic Committee Work System" and the establishment of an "ESG Management Method" [5][7] Group 2 - The company has developed a valuation enhancement plan in response to regulatory requirements due to its stock price being below the net asset value per share for 12 consecutive months [28][29] - The plan focuses on strengthening core business, improving governance, enhancing shareholder returns, and ensuring high-quality information disclosure [30][31][32][34] - The company aims to maintain a cash distribution of at least 20% of the annual distributable profits over the next three years, with a total cash distribution not less than 60% of the average annual distributable profits from the last three years [32][33] Group 3 - The company announced the resignation of Vice President Chen Changbing due to work adjustments, effective immediately upon delivery of the resignation report [42] - Chen will continue to hold other positions within the company, and his resignation will not affect normal operations [42] - The company expressed gratitude for Chen's contributions during his tenure [43]

Summary of the Conference Call for Guoyao Yizhi Company Overview - **Company**: Guoyao Yizhi - **Period**: First half of 2025 Key Financial Performance - Total revenue decreased by 2.62% to 36.797 billion yuan [3] - Net profit attributable to shareholders fell by 10.43% to 666 million yuan [3] - Total assets increased slightly to 550.426 billion yuan, with a stable debt ratio of 57.86% [3] - Earnings per share decreased by 10% to 1.2 yuan [3] - Operating cash flow declined significantly, attributed to extended receivables and negative sales growth in retail [15][16] Distribution Segment Performance - Distribution revenue decreased by 1.09% to 26.783 billion yuan, with net profit down by 7.82% [5] - High-margin products such as biological products, narcotic drugs, and innovative drugs showed strong growth [5] - Collaboration in the Hong Kong and Macau regions was emphasized, along with the integration of new products and innovative drug business [5] - The company expects distribution segment performance to remain stable compared to 2024, despite pressures from procurement expansion and healthcare payment reforms [9] Retail Segment Performance - Retail revenue from Guoda Pharmacy decreased by 6.46% to 10.479 billion yuan, but net profit surged by 215.81% to 17 million yuan [5] - The improvement in net profit was due to continuous optimization of product structure and business model, as well as enhanced operational efficiency [5] - Approximately 1,000 stores were closed to optimize layout, resulting in a total of 8,591 stores by the end of June 2025 [8] Digital Transformation and Smart Logistics - The company implemented digital tools to enhance operational efficiency and management [6] - A "1+4+N" warehouse network layout was established to improve storage capacity and efficiency [6] Organizational Changes and Talent Development - Organizational restructuring was undertaken to enhance resource integration and talent development [7] - Performance and incentive mechanisms were optimized to align with company goals [7] Credit Impairment Losses - Credit impairment losses increased significantly due to extended payment terms and high revenue scale [12] - The company plans to strengthen credit management and control high-risk clients [12][25] Future Strategies and Market Outlook - The company aims to expand its narcotic qualifications and enhance regional coverage [10] - Confidence in increasing market share in Guangxi and Guangdong, despite competitive pressures [11][18] - Focus on improving operational quality and cash flow management in a competitive environment [18] Industry Trends and Challenges - The retail pharmacy sector is expected to face challenges due to increased management and competition, but long-term value remains [17] - The company will continue to adapt to market changes and enhance operational capabilities [17] Conclusion - Guoyao Yizhi is navigating a challenging environment with a focus on optimizing operations, enhancing digital capabilities, and maintaining a stable market presence while addressing credit risks and adapting to industry changes. The outlook remains cautiously optimistic with strategic initiatives aimed at improving profitability and market share.

本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 之任何損失承擔任何責任。 海外監管公告 國藥集團一致藥業股份有限公司 2025 年半年度業績快報 茲載列國藥控股股份有限公司旗下一間 A 股及 B 股於深圳證券交易所上市的附屬公司，國藥集 團一致藥業股份有限公司，在深圳證券交易所網站刊登的《國藥集團一致藥業股份有限公司 2025 年半年度業績快報》，僅供參閱。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 中國，上海 2025 年 8 月 14 日 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 证券代码：000028、200028 证券简称：国药一致、一致B 公告编号：2025-34 国药集团一致药业股份有限公司 於本公告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先生、祖敬先 生、邢永剛先生、陳玉 ...

Financial Performance - Total revenue for the reporting period was ¥37,785,980,620.95, a decrease of 1.57% compared to the same period last year[11]. - Net profit attributable to shareholders was ¥743,487,174.84, down 10.45% year-on-year[11]. - Basic earnings per share decreased by 10.07% to ¥1.34[11]. - Net cash flow from operating activities was ¥929,377,508.78, a decline of 37.47% compared to the previous year[11]. - The company reported a net profit of ¥711,378,482.12, down 10.48% from the previous year[11]. - In the first half of 2024, the company achieved operating revenue of CNY 37.786 billion, a year-on-year decrease of 1.57%, and a net profit attributable to shareholders of CNY 743 million, down 10.45%[22]. - The distribution segment generated operating revenue of CNY 27.079 billion, an increase of 2.11% year-on-year, while net profit was CNY 523 million, a decrease of 1.48%[22]. - The retail segment (Guoda Pharmacy) reported operating revenue of CNY 11.202 billion, a decline of 9.30% year-on-year, with a net profit of -CNY 14 million, down 104.81%[22]. - The company reported a total of non-recurring gains and losses amounting to ¥32,108,692.72[14]. - The company reported a significant decrease in net profit for its subsidiary, Guoda Pharmacy, by 104.81% due to industry policy changes and increased market competition[51]. Assets and Liabilities - Total assets increased by 8.06% to ¥51,405,241,387.83 at the end of the reporting period[11]. - Net assets attributable to shareholders rose by 2.10% to ¥17,779,820,945.40[11]. - The total accounts receivable amounted to ¥22,459,134,687.56, accounting for 43.69% of total assets, an increase of 5.51% from the previous year[42]. - The total inventory at the end of the reporting period was ¥8,381,354,048.18, accounting for 16.30% of total assets, a slight decrease of 0.49% from the previous year[42]. - The company’s short-term borrowings increased to ¥4,441,325,969.54, representing 8.64% of total assets, an increase of 3.15% from the previous year[42]. - Total liabilities reached CNY 30.06 billion, up 13.8% from CNY 26.59 billion at the beginning of the year[109]. - The company's total current liabilities amounted to CNY 27.67 billion, an increase of 13.5% from CNY 24.34 billion[109]. Market and Business Strategy - The company is focusing on transforming its retail model to enhance service quality and reduce reliance on individual account medical insurance payments[17]. - The company aims to integrate its distribution and logistics operations to create a leading supply chain value system in the pharmaceutical industry[18]. - The company is committed to enhancing its professional pharmaceutical service capabilities through partnerships with leading suppliers[18]. - The company is focusing on digital transformation, having launched a business value analysis tool and a collaborative platform to enhance data integration and decision-making[24]. - The company is actively expanding its logistics capabilities, achieving AAAA-level certification as a comprehensive service logistics enterprise[24]. - The company is focusing on enhancing risk management and compliance training to ensure sustainable development[29]. - The company is expanding its online sales through a multi-channel approach, including O2O models and live streaming marketing[29]. - The company is investing heavily in R&D, with a budget allocation of 1,500 million for new technologies and product development[84]. - The company is actively pursuing mergers and acquisitions to strengthen its market position, with a focus on integrating new technologies[91]. Compliance and Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[2]. - The company is committed to compliance and risk management, which is expected to strengthen its competitive position in the market[21]. - The company faces significant policy risks, including declining sales margins due to centralized procurement and increased competition from online pharmacies[53]. - The company is experiencing increased compliance risks due to regulatory changes and heightened scrutiny in the pharmaceutical sector[54]. - The company has reported a total of 117 legal disputes during the reporting period, with a total amount involved of 176.18 million yuan[67]. - The company has established environmental emergency response plans and conducted regular drills to enhance emergency response capabilities[64]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares[2]. - The company has a total of 556,565,077 shares, with 98.71% being unrestricted shares[96]. - The largest shareholder, China National Pharmaceutical Group Co., Ltd., holds 56.06% of the shares, totaling 311,999,988 shares[97]. - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period[103]. - The company has not implemented any employee stock ownership plans or other incentive measures during the reporting period[60]. Future Outlook - The company has provided a performance guidance for the second half of 2024, projecting a revenue growth of approximately 15% year-over-year[84]. - Future guidance includes a projected revenue increase of 20% for the next quarter, reflecting confidence in market expansion strategies[92]. - Overall, the company remains optimistic about future growth, citing strong demand in key segments and a robust pipeline of new products[84]. - The company is focusing on enhancing its core competitiveness and exploring new growth opportunities amid a challenging market environment[55]. Financial Reporting and Accounting Practices - The financial statements for the first half of 2024 were approved by the board on August 27, 2024, ensuring compliance with accounting standards[141]. - The company adheres to the accounting principles established by the Ministry of Finance, ensuring accurate financial reporting and transparency[138]. - The company recognizes expected credit losses based on the present value of cash flow differences between contractual receivables and expected cash flows, considering reasonable and supportable information[153]. - The company recognizes revenue when control of goods or services is transferred to customers, typically at the point of customer acceptance[190]. - The company has established special reserve funds and materials for emergency responses, funded by the government, and manages these reserves dynamically[197].

Financial Performance - The company's operating revenue for 2023 reached ¥75.48 billion, an increase of 2.77% compared to ¥73.44 billion in 2022[19]. - Net profit attributable to shareholders for 2023 was ¥1.60 billion, reflecting a growth of 7.57% from ¥1.49 billion in 2022[19]. - The net cash flow from operating activities increased by 14.71% to ¥2.94 billion, up from ¥2.56 billion in the previous year[19]. - Basic earnings per share for 2023 were ¥2.87, a 7.49% increase from the adjusted ¥2.67 in 2022[19]. - Total assets at the end of 2023 amounted to ¥47.57 billion, marking an 11.63% increase from ¥42.62 billion at the end of 2022[19]. - The net assets attributable to shareholders increased by 7.99% to ¥17.41 billion, compared to ¥16.13 billion at the end of 2022[19]. - The total profit for 2023 was 2.473 billion yuan, an increase of 7.02% compared to the previous year[48]. - The net profit for 2023 reached 1.958 billion yuan, reflecting a year-on-year growth of 10.54%[48]. - The distribution business generated revenue of 51.957 billion yuan in 2023, with a year-on-year increase of 3.50%[48]. - The retail business, represented by Guoda Pharmacy, achieved revenue of 24.409 billion yuan, growing by 1.26% year-on-year[49]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of ¥6.8 per 10 shares, totaling approximately ¥556.57 million based on the current share base[3]. - In 2023, the company distributed cash dividends of RMB 8.00 per 10 shares, totaling RMB 378,464,252.36, which represents 100% of the profit distribution amount[157]. Market and Industry Trends - The average price reduction from the eighth and ninth batches of national drug procurement was 56% and 58%, respectively, contributing to significant cost savings in the healthcare sector[31]. - The national medical insurance drug list was adjusted to include 3,088 types of drugs, with 126 new drugs added in 2023, indicating a growing range of available treatments[32]. - The pharmaceutical retail market is projected to exceed CNY 800 billion by 2030, with retail channels expected to account for 40% of the market share[101]. - The company is positioned to benefit from ongoing healthcare reforms and increased government support for the pharmaceutical industry, particularly in the Guangdong-Hong Kong-Macao Greater Bay Area[30]. Operational Developments - The company has established four large automated logistics centers and 23 distribution centers, enhancing its logistics network in the Guangdong region[45]. - The company is actively pursuing digital transformation, integrating AI, big data, and 5G technologies into its supply chain solutions[45]. - The company is adapting to new policies allowing retail pharmacies to sell non-pharmaceutical products, which will enhance profitability and counteract the impact of declining drug prices[41]. - The company is focusing on a diversified service transformation strategy, enhancing its service capabilities and maintaining a leading market share in the pharmaceutical distribution sector[44]. Research and Development - The company completed six R&D projects in 2023, focusing on cold chain, operational metrics, visual recognition, and customer service[52]. - Total R&D expenses increased by 195.81% to ¥26,821,075.48 in 2023 from ¥9,066,902.05 in 2022[84]. - The number of R&D personnel rose by 162.50% to 126 in 2023, compared to 48 in 2022[85]. - The company is investing heavily in R&D, with a budget allocation of 500 million RMB for new drug development[130]. Risk Management and Compliance - The company has not reported any significant risks that could materially affect its operations during the reporting period[3]. - The company is committed to compliance and maintaining competitive advantages amid stringent regulatory environments in the pharmaceutical industry[103]. - The company is addressing cash flow risks due to prolonged payment cycles and increased financing costs resulting from economic slowdowns[105]. - The company has implemented a robust internal control system that includes risk identification and management measures[160]. Corporate Governance - The company operates independently from its controlling shareholders in terms of business, personnel, assets, and finance, ensuring complete operational autonomy[116]. - The company has established an independent financial department and accounting system, with no financial personnel holding positions or receiving compensation from the controlling shareholders[118]. - The company has a complete governance structure with distinct roles for the board of directors, supervisory board, and management team[116]. - The company has a diverse leadership team, with members having extensive backgrounds in the pharmaceutical industry, including over 27 years of experience for the president, Liu Yong[125]. Environmental and Social Responsibility - The company has not faced any administrative penalties related to environmental issues during the reporting period[167]. - All key pollution monitoring units have established pollution prevention facilities and are continuously investing in upgrades to enhance their capabilities[168]. - The company's 2023 ESG report will be released alongside the Q1 2024 report, providing insights into its environmental and social responsibility efforts[170].

Financial Performance - The company's revenue for Q3 2023 was CNY 18.20 billion, a decrease of 1.57% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2023 was CNY 359.41 million, down 3.75% year-on-year[5]. - For the first nine months of 2023, the company achieved a total revenue of CNY 56.59 billion, an increase of 3.61% year-on-year[6]. - The retail segment reported revenue of CNY 17.72 billion for the first nine months, growing by 6.37%, with net profit increasing by 80.27%[6]. - The distribution segment generated revenue of CNY 39.57 billion, a year-on-year increase of 2.43%, but net profit decreased by 0.57%[6]. - Total operating revenue for the third quarter reached ¥56.59 billion, an increase of 3.6% compared to ¥54.62 billion in the same period last year[21]. - Total operating costs amounted to ¥54.98 billion, up 3.4% from ¥53.17 billion year-on-year[21]. - Net profit for the quarter was ¥1.45 billion, representing a 19.0% increase from ¥1.22 billion in the previous year[22]. - Earnings per share (EPS) for the quarter was ¥2.14, compared to ¥1.88 in the same period last year, reflecting a growth of 13.8%[22]. - The total comprehensive income for the quarter was ¥1.45 billion, compared to ¥1.22 billion, reflecting a growth of 18.8% year-on-year[22]. Assets and Liabilities - The company's total assets as of the end of Q3 2023 were CNY 50.74 billion, reflecting a growth of 19.06% compared to the previous year[5]. - As of September 30, 2023, total assets reached CNY 50.74 billion, an increase from CNY 42.62 billion at the beginning of the year, reflecting a growth of approximately 18.5%[18]. - Current assets amounted to CNY 39.70 billion, up from CNY 31.71 billion at the start of the year, indicating a growth of about 25.1%[18]. - The total liabilities increased to ¥30.27 billion, up from ¥23.17 billion, indicating a growth of 30.5% year-on-year[21]. - The total liabilities of the company were not explicitly stated but can be inferred to have increased in line with asset growth, indicating potential leverage[18]. Cash Flow - Cash flow from operating activities for the first nine months was CNY 1.47 billion, a decrease of 28.78% year-on-year[5]. - Cash received from operating activities increased by CNY 198.30 million, a growth of 40.98%, due to increased receipts from reserve funds and deposits[12]. - The cash inflow from operating activities for the period was CNY 53,825,819,839.45, a decrease of 4.3% compared to CNY 56,601,974,140.25 in the previous period[23]. - The net cash flow from operating activities was CNY 1,465,469,101.73, down 28.8% from CNY 2,057,795,818.15 in the same period last year[23]. - The cash inflow from financing activities was CNY 1,420,106,804.21, down 16.5% from CNY 1,701,018,741.55 in the previous period[24]. - The net cash flow from financing activities was -CNY 2,014,650,640.63, worsening from -CNY 942,013,590.74 in the previous period[24]. - The total cash and cash equivalents at the end of the period stood at CNY 4,827,559,248.03, down from CNY 5,732,553,872.11 in the previous period[24]. Investments and Expenses - R&D expenses increased by CNY 17.96 million, a growth of 100%, due to expenditures on medical management and smart service platform development[11]. - Research and development expenses for the quarter were ¥17.96 million, indicating ongoing investment in innovation[21]. - Investment income increased by CNY 115.49 million, a growth of 103.50%, mainly from reduced receivables factoring and improved performance of joint ventures[11]. - The company reported an investment income of ¥227.06 million, significantly higher than ¥111.58 million from the previous year, showing a growth of 103.5%[21]. Market Outlook - The company is focusing on expanding its market presence and enhancing product development, although specific new products or technologies were not detailed in the report[17]. - Future outlook remains positive with expectations of continued growth in both revenue and market share, driven by strategic initiatives and potential acquisitions[17]. Accounts Management - The company reported a significant increase in accounts receivable, which rose by 68.65% compared to the beginning of the year, primarily due to delayed payments from downstream customers[10]. - Accounts receivable increased significantly to CNY 23.21 billion from CNY 13.76 billion, representing a rise of approximately 68.5%[18]. - Accounts payable increased by CNY 4,252.59 million, a growth of 51.81%, driven by increased business volume and procurement[11]. - The company reported a significant increase in receivables, which may indicate strong sales performance but also raises concerns about cash flow management[18].

证券代码：000028 、200028 证券简称：国药一致、一致B 公告编号：2023-23 国药集团一致药业股份有限公司 第九届董事会第十四次会议决议公告 本公司及董事全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 国药集团一致药业股份有限公司（以下简称"公司"或"国药一致"） 第九届董事会第十四次会议于2023年8月14日以电话、传真和电子邮 件方式发出通知和文件材料，会议于2023年8月25日以现场会议（结 合视频会议）方式在广州+上海召开。董事长林敏先生主持会议。应 参加会议董事10名，亲自出席会议董事10名。公司监事、高管列席了 会议。会议召开程序符合《公司法》、《公司章程》的有关规定。本 次会议听取了公司总经理2023年半年度工作报告及国大药房总经理 2023年上半年管控提升情况汇报，审议了下列事项并形成相关决议。 为优化物流一体化运作，优化组织管理架构，提高运营效率和管 理水平，董事会同意由公司全资孙公司国药控股广东物流有限公司 （简称"国控广东物流"）吸收合并全资子公司国药控股深圳物流有 限公司（以下简称"国控深圳物流"）全部资产、负债、权益、人员及 业务（ ...